Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics.

Trial Profile

Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2014

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jul 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 10 Apr 2012 Actual patient number (546) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top